pediatric patients - United Kingdom News Beep

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

August 19, 2026

Teva Pharmaceutical Industries Ltd Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA…

MMedication

FDA Greenlights Glenmark's Ryaltris Allergy Spray for Children Ages 6-12, ETPharma

July 22, 2026

Mumbai: Glenmark Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved the expanded use of…

MMedication

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

June 27, 2026

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or…

MMedication

Novo Nordisk Expands GLP-1 Reach With Oral Ozempic And Pediatric Push

May 2, 2026

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…

MMedication

FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

August 6, 2025

Teva Pharmaceutical Industries Ltd FDA approves single-dose AJOVY® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in…